KR20060111536A - 생물학적 활성 메틸렌 블루 유도체(２)의 개발 - Google Patents
생물학적 활성 메틸렌 블루 유도체(２)의 개발 Download PDFInfo
- Publication number
- KR20060111536A KR20060111536A KR1020067010376A KR20067010376A KR20060111536A KR 20060111536 A KR20060111536 A KR 20060111536A KR 1020067010376 A KR1020067010376 A KR 1020067010376A KR 20067010376 A KR20067010376 A KR 20067010376A KR 20060111536 A KR20060111536 A KR 20060111536A
- Authority
- KR
- South Korea
- Prior art keywords
- phenothiazine
- ium
- compound
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011161 development Methods 0.000 title description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical class C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 201
- 239000003814 drug Substances 0.000 claims abstract description 37
- 208000015181 infectious disease Diseases 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 230000001954 sterilising effect Effects 0.000 claims abstract description 25
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 23
- 230000000813 microbial effect Effects 0.000 claims abstract description 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 20
- 229920000642 polymer Polymers 0.000 claims abstract description 20
- 239000012530 fluid Substances 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 16
- 150000001450 anions Chemical class 0.000 claims abstract description 15
- 239000004599 antimicrobial Substances 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- 239000002131 composite material Substances 0.000 claims abstract description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 7
- -1 n- Pentyl compounds Chemical class 0.000 claims description 33
- 125000004122 cyclic group Chemical group 0.000 claims description 30
- 229910052757 nitrogen Inorganic materials 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 27
- 230000000845 anti-microbial effect Effects 0.000 claims description 20
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 239000003443 antiviral agent Substances 0.000 claims description 10
- 230000002779 inactivation Effects 0.000 claims description 7
- RCQSSHFSDZTVBX-UHFFFAOYSA-N C1=CC=C2N=C3C(N)=CC=CC3=[S+]C2=C1 Chemical compound C1=CC=C2N=C3C(N)=CC=CC3=[S+]C2=C1 RCQSSHFSDZTVBX-UHFFFAOYSA-N 0.000 claims description 6
- VHRFFLDZMUEBFY-UHFFFAOYSA-N [7-(dibutylamino)phenothiazin-3-ylidene]-dipropylazanium Chemical compound C1=CC(N(CCC)CCC)=CC2=[S+]C3=CC(N(CCCC)CCCC)=CC=C3N=C21 VHRFFLDZMUEBFY-UHFFFAOYSA-N 0.000 claims description 6
- MRICIFFMXVBBLZ-UHFFFAOYSA-N [7-(dihexylamino)phenothiazin-3-ylidene]-dipropylazanium Chemical compound C1=CC(N(CCC)CCC)=CC2=[S+]C3=CC(N(CCCCCC)CCCCCC)=CC=C3N=C21 MRICIFFMXVBBLZ-UHFFFAOYSA-N 0.000 claims description 6
- XYTHRJRWMIRVMF-UHFFFAOYSA-N [7-(dipentylamino)phenothiazin-3-ylidene]-dipropylazanium Chemical compound C1=CC(N(CCC)CCC)=CC2=[S+]C3=CC(N(CCCCC)CCCCC)=CC=C3N=C21 XYTHRJRWMIRVMF-UHFFFAOYSA-N 0.000 claims description 6
- RTNUTCOTGVKVBR-UHFFFAOYSA-N 4-chlorotriazine Chemical class ClC1=CC=NN=N1 RTNUTCOTGVKVBR-UHFFFAOYSA-N 0.000 claims description 5
- GHOVSOBLWMYIBS-UHFFFAOYSA-N [7-(2-ethylpiperidin-1-yl)phenothiazin-3-ylidene]-dipentylazanium Chemical compound C=1C2=[S+]C3=CC(N(CCCCC)CCCCC)=CC=C3N=C2C=CC=1N1CCCCC1CC GHOVSOBLWMYIBS-UHFFFAOYSA-N 0.000 claims description 5
- NUAVPGFEFWFSMV-UHFFFAOYSA-N [7-(2-methylpyrrolidin-1-yl)phenothiazin-3-ylidene]-dipentylazanium Chemical compound C=1C2=[S+]C3=CC(N(CCCCC)CCCCC)=CC=C3N=C2C=CC=1N1CCCC1C NUAVPGFEFWFSMV-UHFFFAOYSA-N 0.000 claims description 5
- INWAQNVCHFCCQS-UHFFFAOYSA-N [7-(diethylamino)phenothiazin-3-ylidene]-dipropylazanium Chemical compound C1=CC(N(CC)CC)=CC2=[S+]C3=CC(N(CCC)CCC)=CC=C3N=C21 INWAQNVCHFCCQS-UHFFFAOYSA-N 0.000 claims description 5
- JUTJTSGMGVYBGB-UHFFFAOYSA-N [7-(dipropylamino)phenothiazin-3-ylidene]-dimethylazanium Chemical compound C1=CC(=[N+](C)C)C=C2SC3=CC(N(CCC)CCC)=CC=C3N=C21 JUTJTSGMGVYBGB-UHFFFAOYSA-N 0.000 claims description 5
- CYTHBCPFWGYCLT-UHFFFAOYSA-N [7-[bis(3-methylbutyl)amino]phenothiazin-3-ylidene]-dibutylazanium Chemical compound C1=CC(N(CCC(C)C)CCC(C)C)=CC2=[S+]C3=CC(N(CCCC)CCCC)=CC=C3N=C21 CYTHBCPFWGYCLT-UHFFFAOYSA-N 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 230000000843 anti-fungal effect Effects 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 5
- AVMGAZVQTLXTGP-UHFFFAOYSA-N 3-piperidin-1-ium-1-ylidene-7-piperidin-1-ylphenothiazine Chemical compound C1CCCCN1C1=CC=C(N=C2C(=CC(C=C2)=[N+]2CCCCC2)S2)C2=C1 AVMGAZVQTLXTGP-UHFFFAOYSA-N 0.000 claims description 4
- MGXRGTGRPPCSHS-UHFFFAOYSA-N 7-morpholin-4-ium-4-ylidene-n,n-dipentylphenothiazin-3-amine Chemical compound C1=C2SC3=CC(N(CCCCC)CCCCC)=CC=C3N=C2C=CC1=[N+]1CCOCC1 MGXRGTGRPPCSHS-UHFFFAOYSA-N 0.000 claims description 4
- IKBPFZFNMLDNRP-UHFFFAOYSA-N 7-morpholin-4-ium-4-ylidene-n,n-dipropylphenothiazin-3-amine Chemical compound C1=C2SC3=CC(N(CCC)CCC)=CC=C3N=C2C=CC1=[N+]1CCOCC1 IKBPFZFNMLDNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003429 antifungal agent Substances 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- SJQXXTXHJKJSQT-UHFFFAOYSA-N n,n-dibutyl-7-morpholin-4-ium-4-ylidenephenothiazin-3-amine Chemical compound C1=C2SC3=CC(N(CCCC)CCCC)=CC=C3N=C2C=CC1=[N+]1CCOCC1 SJQXXTXHJKJSQT-UHFFFAOYSA-N 0.000 claims description 4
- REPBYHXZBOAMGH-UHFFFAOYSA-N [7-(dibutylamino)phenothiazin-3-ylidene]-dipentylazanium Chemical compound C1=CC(N(CCCC)CCCC)=CC2=[S+]C3=CC(N(CCCCC)CCCCC)=CC=C3N=C21 REPBYHXZBOAMGH-UHFFFAOYSA-N 0.000 claims description 3
- XUMHDWMEILPJMS-UHFFFAOYSA-N [7-(dioctylamino)phenothiazin-3-ylidene]-dimethylazanium Chemical compound C1=CC(=[N+](C)C)C=C2SC3=CC(N(CCCCCCCC)CCCCCCCC)=CC=C3N=C21 XUMHDWMEILPJMS-UHFFFAOYSA-N 0.000 claims description 3
- 230000034994 death Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000003504 photosensitizing agent Substances 0.000 abstract description 36
- 238000002428 photodynamic therapy Methods 0.000 abstract description 29
- 238000000034 method Methods 0.000 abstract description 14
- 229940022399 cancer vaccine Drugs 0.000 abstract description 2
- 238000009566 cancer vaccine Methods 0.000 abstract description 2
- 238000001514 detection method Methods 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000005856 abnormality Effects 0.000 abstract 1
- 231100000270 photocytotoxic Toxicity 0.000 abstract 1
- 230000000383 photocytotoxic effect Effects 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 47
- 206010028980 Neoplasm Diseases 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 32
- 241000894006 Bacteria Species 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 30
- 239000000243 solution Substances 0.000 description 27
- 230000001580 bacterial effect Effects 0.000 description 25
- 238000005286 illumination Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 16
- 230000006378 damage Effects 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 241000222122 Candida albicans Species 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 206010052428 Wound Diseases 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 13
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 13
- 229960000907 methylthioninium chloride Drugs 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 238000004949 mass spectrometry Methods 0.000 description 12
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 206010054094 Tumour necrosis Diseases 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 230000002538 fungal effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 6
- 230000002132 lysosomal effect Effects 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 229950000688 phenothiazine Drugs 0.000 description 5
- 239000008057 potassium phosphate buffer Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- GZCQBWPKNZFNPF-UHFFFAOYSA-M 3,7-dibromophenothiazin-5-ium;bromide Chemical compound [Br-].C1=CC(Br)=CC2=[S+]C3=CC(Br)=CC=C3N=C21 GZCQBWPKNZFNPF-UHFFFAOYSA-M 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010034972 Photosensitivity reaction Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 206010048038 Wound infection Diseases 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- YUBCFVPTXZHLKM-UHFFFAOYSA-J phenothiazin-5-ium;tetraiodide;hydrate Chemical compound O.[I-].[I-].[I-].[I-].C1=CC=CC2=NC3=CC=CC=C3[S+]=C21.C1=CC=CC2=NC3=CC=CC=C3[S+]=C21.C1=CC=CC2=NC3=CC=CC=C3[S+]=C21.C1=CC=CC2=NC3=CC=CC=C3[S+]=C21 YUBCFVPTXZHLKM-UHFFFAOYSA-J 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000003471 mutagenic agent Substances 0.000 description 3
- 231100000707 mutagenic chemical Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229920002120 photoresistant polymer Polymers 0.000 description 3
- 230000036211 photosensitivity Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 239000012137 tryptone Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- AGWBRZUOPBTCHK-UHFFFAOYSA-N 10h-phenothiazin-10-ium;bromide Chemical compound [Br-].C1=CC=C2[NH2+]C3=CC=CC=C3SC2=C1 AGWBRZUOPBTCHK-UHFFFAOYSA-N 0.000 description 2
- OWPUOLBODXJOKH-UHFFFAOYSA-N 2,3-dihydroxypropyl prop-2-enoate Chemical compound OCC(O)COC(=O)C=C OWPUOLBODXJOKH-UHFFFAOYSA-N 0.000 description 2
- LKZIEAUIOCGXBY-AOIFVJIMSA-N 3-hydroxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)C(O)CC(O)=O LKZIEAUIOCGXBY-AOIFVJIMSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 238000010953 Ames test Methods 0.000 description 2
- 231100000039 Ames test Toxicity 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 description 2
- 229910005965 SO 2 Inorganic materials 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 206010070835 Skin sensitisation Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- JXBCJUPBVRELNY-UHFFFAOYSA-N [7-(diethylamino)phenothiazin-3-ylidene]-diethylazanium Chemical compound C1=CC(N(CC)CC)=CC2=[S+]C3=CC(N(CC)CC)=CC=C3N=C21 JXBCJUPBVRELNY-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000007539 photo-oxidation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 231100000370 skin sensitisation Toxicity 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AGJAUFUNZWHLKE-UHFFFAOYSA-N (2E,4E)-N-isobutyl-2,4-tetradecadienamide Natural products CCCCCCCCCC=CC=CC(=O)NCC(C)C AGJAUFUNZWHLKE-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- ZXOXWWSLOJUKOW-UHFFFAOYSA-N 2-[2-hydroxyethyl(pentyl)amino]heptan-1-ol Chemical compound CCCCCC(CO)N(CCO)CCCCC ZXOXWWSLOJUKOW-UHFFFAOYSA-N 0.000 description 1
- XFOHWECQTFIEIX-UHFFFAOYSA-N 2-nitrofluorene Chemical compound C1=CC=C2C3=CC=C([N+](=O)[O-])C=C3CC2=C1 XFOHWECQTFIEIX-UHFFFAOYSA-N 0.000 description 1
- YHQDZJICGQWFHK-UHFFFAOYSA-N 4-nitroquinoline N-oxide Chemical compound C1=CC=C2C([N+](=O)[O-])=CC=[N+]([O-])C2=C1 YHQDZJICGQWFHK-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 208000009129 Ear Neoplasms Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010052359 Gingival abscess Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 206010061304 Nail infection Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- PLGPSDNOLCVGSS-UHFFFAOYSA-N Tetraphenylcyclopentadienone Chemical compound O=C1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 PLGPSDNOLCVGSS-UHFFFAOYSA-N 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010068796 Wound contamination Diseases 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- SRNSQEKEXQHBIE-UHFFFAOYSA-N [I-](I)I.C(CCCC)N(CCCCC)C=1C=CC2=NC3=CC=CC=C3[S+]=C2C1 Chemical compound [I-](I)I.C(CCCC)N(CCCCC)C=1C=CC2=NC3=CC=CC=C3[S+]=C2C1 SRNSQEKEXQHBIE-UHFFFAOYSA-N 0.000 description 1
- VPYGIJMTWLXMTE-UHFFFAOYSA-N [Ti]N=[N+]=[N-] Chemical compound [Ti]N=[N+]=[N-] VPYGIJMTWLXMTE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- GJJYZOBRHIMORS-GQOAHPRESA-K aloglutamol Chemical compound OCC(N)(CO)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Al](O)O GJJYZOBRHIMORS-GQOAHPRESA-K 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- YCSBALJAGZKWFF-UHFFFAOYSA-N anthracen-2-amine Chemical compound C1=CC=CC2=CC3=CC(N)=CC=C3C=C21 YCSBALJAGZKWFF-UHFFFAOYSA-N 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000001309 degenerative myopia Diseases 0.000 description 1
- 230000004340 degenerative myopia Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical group C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 208000031083 ear cancer Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000022168 hypermenorrhea Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000022924 malignant ear neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000009526 moderate injury Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- PXSXRABJBXYMFT-UHFFFAOYSA-N n-hexylhexan-1-amine Chemical compound CCCCCCNCCCCCC PXSXRABJBXYMFT-UHFFFAOYSA-N 0.000 description 1
- JACMPVXHEARCBO-UHFFFAOYSA-N n-pentylpentan-1-amine Chemical compound CCCCCNCCCCC JACMPVXHEARCBO-UHFFFAOYSA-N 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- PCTUFUANGGOZAG-UHFFFAOYSA-M phenothiazin-5-ium;iodide Chemical compound [I-].C1=CC=CC2=NC3=CC=CC=C3[S+]=C21 PCTUFUANGGOZAG-UHFFFAOYSA-M 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0327672.2 | 2003-11-28 | ||
| GBGB0327672.2A GB0327672D0 (en) | 2003-11-28 | 2003-11-28 | Developments in biologically active methylene blue derivatives (phenothiazines) |
| GB0329809A GB0329809D0 (en) | 2003-12-23 | 2003-12-23 | Developments in biologically active methylene blue derivatives (2) (phenothiazines) |
| GB0329809.8 | 2003-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060111536A true KR20060111536A (ko) | 2006-10-27 |
Family
ID=34655223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067010376A Withdrawn KR20060111536A (ko) | 2003-11-28 | 2004-11-22 | 생물학적 활성 메틸렌 블루 유도체(２)의 개발 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1687286A1 (https=) |
| JP (1) | JP2007512297A (https=) |
| KR (1) | KR20060111536A (https=) |
| AU (1) | AU2004295148A1 (https=) |
| BR (1) | BRPI0416928A (https=) |
| CA (1) | CA2547556A1 (https=) |
| WO (1) | WO2005054217A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176308B2 (en) * | 2002-06-17 | 2007-02-13 | Verification Technologies, Inc. | Processes for preparing novel methylene blue derivative |
| SI2322517T1 (sl) | 2004-09-23 | 2019-06-28 | Wista Laboratories Ltd. | Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC) |
| CN101084204B (zh) * | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| WO2007110630A1 (en) * | 2006-03-29 | 2007-10-04 | Wista Laboratories Ltd. | Thioninium compounds and their use |
| SI2004155T1 (en) | 2006-03-29 | 2018-05-31 | Wista Laboratories Ltd. | Inhibitors of protein aggregation |
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| MY148145A (en) | 2006-07-11 | 2013-03-15 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| US8227459B2 (en) * | 2007-04-03 | 2012-07-24 | Prosetta Antiviral Inc. | Diamino-phenothiazinyl derivatives as antiviral treatments |
| FR2920775B1 (fr) | 2007-09-07 | 2009-11-06 | Pharma Hydro Dev P H D Soc Par | Nouveaux composes diaminophenothiazine, leur procede de preparation et leurs utilisations. |
| GB2453564A (en) * | 2007-10-11 | 2009-04-15 | Liverpool John Moores University | Ring-fused derivatives of 3,7-diamino- phenothiazinium & phenoselenazinium salts for use as antimicrobial agents |
| JP5868955B2 (ja) * | 2010-04-30 | 2016-02-24 | プロセッタ アンチバイラル インコーポレイテッド | 抗ウイルス化合物 |
| WO2012085250A1 (en) * | 2010-12-22 | 2012-06-28 | Ortner Cleanroom Engineering Gmbh | Clean room device with movable electromagnetic radiation source |
| EP2654806B1 (en) * | 2010-12-22 | 2019-05-22 | Ortner Cleanroom Engineering GmbH | Photodynamic control of microbial growth on surfaces |
| JP5898701B2 (ja) | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
| WO2012125983A1 (en) | 2011-03-17 | 2012-09-20 | Prosetta Antiviral Inc. | Antiviral treatments |
| EP2694478B1 (en) * | 2011-04-04 | 2018-08-22 | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University | Methylene violet analogs as multifunctional radical quenchers for the treatment of mitochondrial dysfunction |
| EP2699241B1 (en) * | 2011-04-20 | 2016-07-27 | Prosetta Antiviral Inc. | Antiviral compounds |
| US20120301904A1 (en) | 2011-04-26 | 2012-11-29 | Prosetta Antiviral, Inc | Multiprotein assemblies |
| AU2013341383B2 (en) | 2012-11-12 | 2017-08-24 | The Roger B. And Ann K. Mcnamee Trust U/T/A/D | Systems and methods for communicating a live event to users using the internet |
| CN105612148B (zh) * | 2013-08-15 | 2018-09-14 | 益友制药私人有限公司 | 用于纯化二氨基吩噻嗪化合物的方法 |
| WO2016031875A1 (ja) | 2014-08-27 | 2016-03-03 | 富士フイルム株式会社 | 光線力学療法用組成物、殺菌方法、殺菌システムおよび殺菌システムの作動方法 |
| EP3397623A1 (en) | 2015-12-28 | 2018-11-07 | John V. Frangioni | Method of preparing diaminophenothiazinium |
| FR3063495B1 (fr) * | 2017-03-02 | 2019-04-05 | Provepharm Life Solutions | Procede de preparation de l’iodure de 3,7-bis(dimethylamino)phenothiazine-5-ylium |
| CA3072418A1 (en) * | 2017-08-08 | 2019-02-14 | Board Of Trustees Of Michigan State University | Tunable luminescent organic salts for enhanced imaging and photodynamic therapy |
| US12215234B2 (en) | 2019-09-21 | 2025-02-04 | RK Pharma Solutions LLC | Process for the purification of methylene blue |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2794786A (en) * | 1955-05-27 | 1957-06-04 | Security Trust Company | Thionin dye-ion exchange resin indicator compounds |
| US3579339A (en) * | 1967-05-23 | 1971-05-18 | Du Pont | Photopolymerizable dispersions and elements containing nonmigratory photoreducible dyes |
| US3641016A (en) * | 1968-02-16 | 1972-02-08 | Egyt Gyogyszervegyeszeti Gyar | Thionine derivatives |
| FR2196082A5 (https=) * | 1972-08-07 | 1974-03-08 | Lucien Internal | |
| US4426446A (en) * | 1981-02-03 | 1984-01-17 | Hoffmann-La Roche Inc. | Leucocyte adherence inhibition assay for detection of cancer |
| JPS638652A (ja) * | 1986-06-27 | 1988-01-14 | Ricoh Co Ltd | 静電荷像現像用トナ− |
| CS264623B1 (cs) * | 1987-06-19 | 1989-08-14 | Capek Antonin | Biocidní prostředek |
| CA2055463C (en) * | 1989-05-11 | 1997-09-30 | Raymond F. Schinazi | Antiviral therapy using thiazine and xanthene dyes |
| WO1991016911A1 (en) * | 1990-05-01 | 1991-11-14 | The American National Red Cross | Decontamination of whole blood and cellular components by phenthiazin-5-ium-dyes plus light |
| US5220009A (en) * | 1990-05-03 | 1993-06-15 | Yeda Research And Development Company Limited | Phenothiazinium salts and their use for disinfecting aqueous effluents |
| US5344928A (en) * | 1991-04-26 | 1994-09-06 | Takeda Chemical Industries, Ltd. | Phenothiazine derivatives, their production and use |
| US5527704A (en) * | 1994-12-06 | 1996-06-18 | Baxter International Inc. | Apparatus and method for inactivating viral contaminants in body fluids |
| US5830526A (en) * | 1994-12-28 | 1998-11-03 | Fibermark, Inc. | Light-activated antimicrobial and antiviral materials |
| DE19640722A1 (de) * | 1996-10-02 | 1998-04-23 | Stiftung Fuer Lasertechnologie | Verfahren und Vorrichtung zur Zell- und Gewebezerstörung durch Methylen Blau (MB+) in Verbindung mit polychromatischem Licht im roten Frequenzbereich |
| DE19640758C2 (de) * | 1996-10-02 | 1999-11-04 | Rafael Lachky | Mittel zur Behandlung von Diskusfischen |
| US6190609B1 (en) * | 1996-11-19 | 2001-02-20 | Baxter International Inc. | Methods and apparatus for inactivating contaminants in biological fluid |
| WO1999004628A1 (en) * | 1997-07-28 | 1999-02-04 | Dermatolazer Technologies Ltd. | Phototherapy based method for treating pathogens and composition for effecting same |
| US5811471A (en) * | 1997-09-15 | 1998-09-22 | Shanbrom Technologies Llc | Disinfectant plastic sponge material |
| AU3371799A (en) * | 1998-03-30 | 1999-10-18 | Fibermark, Inc. | Light-activated antimicrobial polymeric materials |
| AUPP751298A0 (en) * | 1998-12-04 | 1999-01-07 | Csl Limited | Inactivation of non-enveloped viruses |
| JP2002534483A (ja) * | 1999-01-15 | 2002-10-15 | ライト サイエンシーズ コーポレイション | 代謝性骨障害または骨転移のための治療的組成物 |
| RU2184737C2 (ru) * | 1999-02-23 | 2002-07-10 | Институт нефтехимии и катализа АН РБ и УНЦ РАН | Органические комплексы цефалоспориновых антибиотиков, обладающие антимикробными свойствами |
| WO2001049328A1 (en) * | 2000-01-05 | 2001-07-12 | The American National Red Cross | Photodynamic inactivation of pathogens in blood by phenothiazines and oxygen |
| GB0002719D0 (en) * | 2000-02-08 | 2000-03-29 | Tissuemed Ltd | Thermal ablation of tissue |
| RU2176505C2 (ru) * | 2000-02-15 | 2001-12-10 | Третьяков Василий Васильевич | Средство, обладающее противовирусной активностью, на основе соединений серебра и золота с тиазином и способ его получения |
| CA2401624C (en) * | 2000-02-26 | 2011-08-16 | Merrill A. Biel | Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| JP2004502704A (ja) * | 2000-06-30 | 2004-01-29 | ジラ・インク | 上皮癌の検出のためのメチレンブルー診断剤および診断方法 |
| US6881731B1 (en) * | 2000-10-23 | 2005-04-19 | Shanbrom Technologies, Llc | Enhancers for microbiological disinfection |
| US6623513B2 (en) * | 2001-01-19 | 2003-09-23 | Advanced Photodynamic Technologies, Inc. | Apparatus and method of photodynamic eradication of organisms utilizing pyrrolnitrin |
| GB0113121D0 (en) * | 2001-05-30 | 2001-07-18 | Univ Leeds | Biologically active photosensitisers |
| RU2209072C2 (ru) * | 2001-09-25 | 2003-07-27 | Орловский Евгений Владимирович | Антивирусная композиция для лечения вич-инфицированных больных с высокой вирусной нагрузкой |
-
2004
- 2004-11-22 EP EP04798628A patent/EP1687286A1/en not_active Withdrawn
- 2004-11-22 AU AU2004295148A patent/AU2004295148A1/en not_active Abandoned
- 2004-11-22 WO PCT/GB2004/004918 patent/WO2005054217A1/en not_active Ceased
- 2004-11-22 KR KR1020067010376A patent/KR20060111536A/ko not_active Withdrawn
- 2004-11-22 CA CA002547556A patent/CA2547556A1/en not_active Abandoned
- 2004-11-22 JP JP2006540597A patent/JP2007512297A/ja not_active Abandoned
- 2004-11-22 BR BRPI0416928-0A patent/BRPI0416928A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1687286A1 (en) | 2006-08-09 |
| BRPI0416928A (pt) | 2007-01-16 |
| CA2547556A1 (en) | 2005-06-16 |
| AU2004295148A1 (en) | 2005-06-16 |
| WO2005054217A1 (en) | 2005-06-16 |
| JP2007512297A (ja) | 2007-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7371744B2 (en) | Biologically active methylene blue derivatives | |
| KR20060111536A (ko) | 생물학적 활성 메틸렌 블루 유도체(２)의 개발 | |
| AU2002256784A1 (en) | Biologically active methylene blue derivatives | |
| US7407948B2 (en) | Photosensitisers and their uses | |
| ZA200604309B (en) | Developments in biologically active methylene blue derivatives (2) | |
| MXPA06005792A (en) | Developments in biologically active methylene blue derivatives (2) | |
| HK1107563A (en) | Biologically active methylene blue derivatives | |
| AU2007221946A1 (en) | Biologically active methylene blue derivatives | |
| HK1063788B (en) | Biologically active methylene blue derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20060526 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |